How These 4 NZX Stocks performed today - PEB, NWF, HMY, AFT

Source: Phongphan, Shutterstock

Summary

  • Stocks witness a rise or fall due to several reasons like latest announcements, change in a company’s management, and economic events, etc.
  • The main index, NZX 50, was trading up 0.95%, at 12,637.83 points, at the time of writing on 13 April.
  • These 4 companies made important announcements on the NZX on Tuesday.

Markets have been quite volatile recently due to various factors, including vaccine roll-outs and other economy-related factors. Stocks keep on witnessing fluctuation in prices as the economy experiences new changes every day.

NZ benchmark index was trading up 0.95%, at 12,637.83 points, at the time of writing on Tuesday. The index had slipped 0.4% to 12,518.71 points on Monday, weighed down by a fall in its heavyweight stock Fisher & Paykel Healthcare (NZX:FPH, ASX:FPH).

 Image Source: Copyright © 2021 Kalkine Media Pty Ltd

Let’s have a look at the performance of these 4 stocks that have been in spotlight on Tuesday.

Pacific Edge Limited (NZX:PEB)

Pacific Edge Group announced on April 9 that its Cxbladder cancer diagnostic tests are now covered by United Healthcare group (UHG), largest healthcare insurer in the US. The change would help Americans who are searching for better treatment solutions and health outcomes after being diagnosed with bladder cancer.

On 12 April, PEB Group also announced retirement of its CEO, David Darling, from his position on 6 April 2022.

On 13 April, at the time of writing, PEB was trading at $1.18, up 2.61%.

ALSO READ: Here Are 10 Most Traded Stocks On The NZX Today

NZ Windfarms Limited (NZX:NWF)

NZ Windfarms announced completion of third Variable Volume Fixed Price Agreement (VVFPA) for its full production from 1 January 2022 to 30 September 2022. The Group also has an earlier agreement in place for production before 1 January 2022.

The NWF Board noted that its EBITDA will be materially higher in FY2022 than the present year. However, EBITDAF guidance range will be given once the budget is passed by the Board, which is expected to be within the next 3 months.

On 13 April, at the time of writing, NWF was trading flat at $0.21.

Source: Copyright © 2021 Kalkine Media Pty Ltd

Harmoney Corp Limited (NZX:HMY)

Harmoney exceeded $2 billion mark in its total loan origination in Q3 of FY21. The Group’s total loans to new customers rose 60% to $44.1 million in the period, up from $27.5 million in Q2 of FY21.

The key growth driver was new customer acquisition in Australia with $10 million new loan originations delivered in March 2021. The Group’s NZ operations also provided significant growth in new loan originations.

On 13 April, at the time of writing, HMY was trading at $2.27, down 1.3%.

DO READ: Why Are These 6 Stocks Creating A Buzz On NZX – WBC, SCL, AGL, GNE, PEB, VGL?

AFT Pharmaceuticals (NZX:AFT, ASX:AFP)

AFT recently signed agreements to distribute its Crystawash ® Extend, a hand sanitiser developed to knock out the flaws of traditional alcohol-based sanitisers, in the UAE, Oman, Kenya, and Kuwait.

Dr Hartley Atkinson, AFT, MD, expressed pleasure with the new contract with Germany’s Pharma Bavaria International GmbH, which has established networks in the Middle East and Africa. He stated that the deal would help AFT get international networks of partnerships to develop distribution of its unique products.

On 13 April, at the time of writing, AFT was trading at $4.33, up 1.17%.

(NOTE: Currency is reported in NZ Dollar unless stated otherwise)


Disclaimer
The website https://kalkinemedia.com/nz is a service of Kalkine Media New Zealand Limited (Kalkine Media), Company Number: 8107196. The principal purpose of the content on this website is to provide factual information only and does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stock of the company (or companies) or engage in any investment activity under discussion. We are neither licensed nor qualified to provide investment advice through this platform. In providing you with the content on this website, we have not considered your objectives, financial situation or needs. You should make your own enquiries and obtain your own independent advice prior to making any financial decisions.
Some of the images that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed on this website unless stated otherwise. The images that may be used on this website are taken from various sources on the web and are believed to be in public domain. We have used reasonable efforts to accredit the source (public domain/CC0 status) to where it was found and indicated it below the image. The information provided on the website is in good faith, however Kalkine Media does not make any representation or warranty regarding the content, accuracy, or use of the content on the website.
   
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK